Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Income Tax Expense Benefit

Other segment segments

Similar metrics at other companies

ANABBiopharma Company — Income Tax Expense Benefit

$0—

UTLGas — Income Tax Expense Benefit

$11.2M+19.1%

AMP

AMPHPharmaceutical Products — Income Tax Expense Benefit

$3.63M-34.9%

MGEEGas — Income Tax Expense Benefit

$5.26M+5.5%

UFPIAll Other Segments — Income Tax Expense Benefit

$904K+35.1%

COLLSegment — Income Tax Expense (Benefit)

$4.24M+502%

Questions, answered.

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit?

Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — income tax expense benefit of $621K in Q1 2026.

How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit changed year-over-year?

Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit decreased by 31.1% year-over-year, from $901K to $621K.

What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit?

Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit has grown at a -26.8% compound annual growth rate (CAGR), from $8.51M to $4.55M.

What does gyre pharmaceuticals — income tax expense benefit mean?

This represents the total income tax provision or benefit allocated to the specific business segment. It reflects the tax impact of the segment's operations based on applicable jurisdictional tax rates and accounting standards. Investors use this to understand the net impact of taxation on the segment's bottom-line profitability.